A serological investigation in Southern Italy: was SARS-CoV-2 circulating in late 2019?


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
30 11 2022
Historique:
pubmed: 16 3 2022
medline: 15 6 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

In March 2020, the first pandemic caused by a coronavirus was declared by the World Health Organization. Italy was one of the first and most severely affected countries, particularly the northern part of the country. The latest evidence suggests that the virus could have been circulating, at least in Italy, before the first autochthonous SARS-COV-2 case was detected in February 2020. The present study aimed to investigate the presence of antibodies against SARS-CoV-2 in human serum samples collected in the last months of 2019 (September-December) in the Apulia region, Southern Italy. Eight of 455 samples tested proved positive on in-house receptor-binding-domain-based ELISA. Given the month of collection of the positive samples, these findings may indicate early circulation of SARS-CoV-2 in Apulia region in the autumn of 2019. However, it cannot be completely ruled out that the observed sero-reactivity could be an unknown antigen specificity in another virus to which subjects were exposed containing an epitope adventitiously cross-reactive with an epitope of SARS-CoV-2.

Identifiants

pubmed: 35289714
doi: 10.1080/21645515.2022.2047582
pmc: PMC8935457
doi:

Substances chimiques

Antibodies, Viral 0
Epitopes 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2047582

Références

Clin Microbiol Infect. 2020 Dec 2;:
pubmed: 33278571
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Emerg Infect Dis. 2021 Feb;27(2):648-650
pubmed: 33292923
Virology. 2021 Mar;555:35-43
pubmed: 33450669
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Med Virol. 2021 Sep;93(9):5409-5415
pubmed: 33932299
Sci Total Environ. 2020 Sep 20;736:139652
pubmed: 32464333
Tumori. 2021 Oct;107(5):446-451
pubmed: 33176598
Clin Infect Dis. 2021 Jun 15;72(12):e1004-e1009
pubmed: 33252659
J Immunol Methods. 2021 Feb;489:112937
pubmed: 33253698
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Front Cell Infect Microbiol. 2021 Apr 06;11:655896
pubmed: 33889552
PLoS One. 2021 Jul 2;16(7):e0253977
pubmed: 34214116
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3342-3349
pubmed: 33928622
J Infect Dis. 2020 Oct 1;222(9):1452-1461
pubmed: 32766833
Viruses. 2020 Oct 26;12(11):
pubmed: 33114742
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Sci Total Environ. 2021 Jan 1;750:141711
pubmed: 32835962
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Public Health. 2020 Aug;185:99-101
pubmed: 32593056
J Med Virol. 2020 Sep;92(9):1637-1640
pubmed: 32222993
PLoS One. 2021 Mar 22;16(3):e0248918
pubmed: 33750984
Cell Rep. 2020 Jun 2;31(9):107725
pubmed: 32426212
Int J Infect Dis. 2020 Nov;100:112-116
pubmed: 32891737
Environ Int. 2020 Jun;139:105730
pubmed: 32294574
Int J Environ Res Public Health. 2020 Nov 16;17(22):
pubmed: 33207548
Mol Biol Evol. 2021 Jul 29;38(8):3046-3059
pubmed: 33942847
Nature. 2020 Nov;587(7835):534-535
pubmed: 33214725
Eur J Epidemiol. 2021 Feb;36(2):219-222
pubmed: 33548003
Int J Antimicrob Agents. 2020 Jun;55(6):106006
pubmed: 32371096
Br J Dermatol. 2021 May;184(5):970-971
pubmed: 33410129
Sci Rep. 2020 Nov 18;10(1):20048
pubmed: 33208819
Front Pediatr. 2021 May 11;9:620598
pubmed: 34046372
JAMA. 2020 Apr 21;323(15):1488-1494
pubmed: 32125362
Nature. 2021 Feb;590(7844):146-150
pubmed: 33142304
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Med Virol. 2020 Oct;92(10):2096-2104
pubmed: 32383254
Cell. 2020 Nov 12;183(4):1024-1042.e21
pubmed: 32991844
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Environ Res. 2022 Dec;215(Pt 1):113979
pubmed: 36029839

Auteurs

Claudia Maria Trombetta (CM)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Serena Marchi (S)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Simonetta Viviani (S)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Alessandro Manenti (A)

VisMederi srl, Siena, Italy.
VisMederi Research srl, Siena, Italy.

Elisa Casa (E)

VisMederi Research srl, Siena, Italy.

Francesca Dapporto (F)

VisMederi Research srl, Siena, Italy.

Edmond J Remarque (EJ)

Department of Virology, Biomedical Primate Research Centre, Rijswijk, The Netherlands.

Valentina Bollati (V)

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Ilaria Manini (I)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Giacomo Lazzeri (G)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.

Emanuele Montomoli (E)

Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
VisMederi srl, Siena, Italy.
VisMederi Research srl, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH